An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety data, Biohaven revealed in an SEC filing.
The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday.
An epilepsy study of the experimental drug called BHV-7000 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on…
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is…
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel…
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental…
